190 related articles for article (PubMed ID: 33731288)
21. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study.
Rolff HC; Christensen IJ; Vainer B; Svendsen LB; Eefsen RL; Wilhelmsen M; Lund IK; Høyer-Hansen G; Nielsen HJ; Illemann M;
Clin Cancer Res; 2016 May; 22(10):2427-34. PubMed ID: 26673797
[TBL] [Abstract][Full Text] [Related]
23. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
[TBL] [Abstract][Full Text] [Related]
24. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
25. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
27. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S; Sakamoto Y; Denda T; Takashima A; Komatsu Y; Nakamura M; Ohori H; Yamaguchi T; Kobayashi Y; Baba H; Kotake M; Amagai K; Kondo H; Shimada K; Sato A; Yuki S; Okita A; Ouchi K; Komine K; Watanabe M; Morita S; Ishioka C
Cancer Sci; 2021 Apr; 112(4):1567-1578. PubMed ID: 33548159
[TBL] [Abstract][Full Text] [Related]
28. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
29. DNA binding induces conformational transition within human DNA topoisomerase I in solution.
Oleinikov V; Sukhanova A; Mochalov K; Ustinova O; Kudelina I; Bronstein I; Nabiev I
Biopolymers; 2002; 67(6):369-75. PubMed ID: 12209444
[TBL] [Abstract][Full Text] [Related]
30. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
31. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs.
Baglini E; Salerno S; Barresi E; Robello M; Da Settimo F; Taliani S; Marini AM
Eur J Pharm Sci; 2021 Jan; 156():105594. PubMed ID: 33059042
[TBL] [Abstract][Full Text] [Related]
32. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Shen J; Wei J; Wang H; Yue G; Yu L; Yang Y; Xie L; Zou Z; Qian X; Ding Y; Guan W; Liu B
J Transl Med; 2013 Mar; 11():73. PubMed ID: 23517622
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Palshof JA; Høgdall EV; Poulsen TS; Linnemann D; Jensen BV; Pfeiffer P; Tarpgaard LS; Brünner N; Stenvang J; Yilmaz M; Nielsen DL
BMC Cancer; 2017 Jan; 17(1):48. PubMed ID: 28077117
[TBL] [Abstract][Full Text] [Related]
35. Retrospective Study of the Predictive Value of Target Now in Systemic Therapy for Metastatic Colorectal and Gastric Carcinomas.
Cohen JE; Cohen Y; Peretz T; Hubert A
Isr Med Assoc J; 2015 Oct; 17(10):612-5. PubMed ID: 26665314
[TBL] [Abstract][Full Text] [Related]
36. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
37. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
38. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
39. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
Ouchi K; Takahashi S; Yamada Y; Tsuji S; Tatsuno K; Takahashi H; Takahashi N; Takahashi M; Shimodaira H; Aburatani H; Ishioka C
Cancer Sci; 2015 Dec; 106(12):1722-9. PubMed ID: 26426205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
